Industry
Biotechnology
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
May 28, 2024 | 8:17 pm
Portfolio Pulse from Benzinga Newsdesk
May 28, 2024 | 8:16 pm
Portfolio Pulse from Benzinga Newsdesk
May 14, 2024 | 12:29 pm
Portfolio Pulse from Benzinga Newsdesk
May 13, 2024 | 8:46 pm
Portfolio Pulse from Benzinga Newsdesk
March 19, 2024 | 11:05 am
Portfolio Pulse from Benzinga Insights
March 12, 2024 | 9:05 pm
Portfolio Pulse from Benzinga Newsdesk
March 12, 2024 | 2:49 pm
Portfolio Pulse from Happy Mohamed
March 12, 2024 | 12:06 pm
Portfolio Pulse from Benzinga Insights
February 16, 2024 | 1:06 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.